Claims for Patent: 6,136,794
✉ Email this page to a colleague
Summary for Patent: 6,136,794
| Title: | Platelet aggregation inhibition using low molecular weight heparin in combination with a GP IIb/IIIa antagonist |
| Abstract: | A method for inhibiting platelet aggregation in a mammal comprising administering to the mammal a safe and therapeutically effective amount of a GPIIb/IIIa receptor antagonist or a pharmaceutically acceptable salt thereof and a safe and therapeutically effective amount of low molecular weight heparin. A method for inhibiting platelet aggregation in a mammal comprising administering to the mammal a safe and therapeutically effective amount of (2-S-(n-butylsulfonylamino)-3[4-(piperidin-4-yl)butyloxyphenyl]-propionic acid or a pharmaceutically acceptable salt thereof and a safe and therapeutically effective amount of low molecular weight heparin. |
| Inventor(s): | Cook; Jacquelynn J. (Collegeville, PA), Gould; Robert J. (Green Lane, PA), Sax; Frederic L. (Villanova, PA) |
| Assignee: | Merck & Co., Inc. (Rahway, NJ) |
| Application Number: | 09/240,429 |
| Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for patent 6,136,794 |
| Patent Claims: |
1. A method for inhibiting platelet aggregation in a mammal comprising administering to the mammal a safe and therapeutically effective amount of a GPIIb/IIIa receptor
antagonist or a pharmaceutically acceptable salt thereof and a safe and therapeutically effective amount of low molecular weight heparin.
2. A method of claim 1 for inhibiting platelet aggregation in a mammal wherein the GP IIb/IIIa receptor antagonist is (2-S-(n-butylsulfonylamino)-3[4-(piperidin-4-yl)butyloxyphenyl]propionic acid or a pharmaceutically acceptable salt thereof. 3. A method for inhibiting platelet aggregation in a mammal comprising administering to the mammal a safe and therapeutically effective amount of a GPIIb/IIIa receptor antagonist or a pharmaceutically acceptable salt thereof, a safe and therapeutically effective amount of low molecular weight heparin, and a safe and therapeutically effective amount of aspirin. 4. A method of claim 3 for inhibiting platelet aggregation in a mammal wherein the GP IIb/IIIa receptor antagonist is (2-S-(n-butylsulfonylamino)-3[4-(piperidin-4-yl)butyloxyphenyl]propionic acid or a pharmaceutically acceptable salt thereof. 5. A method for inhibiting platelet aggregation in a patient comprising administering to the patient a therapeutically effective amount of a GP IIb/IIIa receptor antagonist or a pharmaceutically acceptable salt thereof and a therapeutically effective amount of a low molecular weight heparin, wherein bleeding time is reduced relative to bleeding time associated with a method comprising administration of unfractionated heparin. |
